Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [20]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- FAB347P - Provider product page
- Provider
- Novus Biologicals
- Product name
- Mouse Monoclonal TRAIL R1/TNFRSF10A Antibody
- Antibody type
- Monoclonal
- Antigen
- S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A, corresponding to Ala24-Asn239
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Vial size
- 100 Tests
- Storage
- Store at 4°C in the dark.
Submitted references Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells.
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin.
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.
The role of selected flavonols in tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) expression on activated RAW 264.7 macrophages.
Chrysin, apigenin and acacetin inhibit tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) on activated RAW264.7 macrophages.
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway.
Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis.
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.
Jo EB, Lee YS, Lee H, Park JB, Park H, Choi YL, Hong D, Kim SJ
BMC cancer 2019 May 24;19(1):496
BMC cancer 2019 May 24;19(1):496
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin.
Xu S, Li D, Li T, Qiao L, Li K, Guo L, Liu Y
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018;51(5):2212-2223
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018;51(5):2212-2223
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y, Tian B, Wang Y, Ding H
Medical science monitor : international medical journal of experimental and clinical research 2017 Oct 26;23:5096-5105
Medical science monitor : international medical journal of experimental and clinical research 2017 Oct 26;23:5096-5105
Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y, Tian B, Wang Y, Ding H
Medical science monitor : international medical journal of experimental and clinical research 2017 Oct 26;23:5096-5105
Medical science monitor : international medical journal of experimental and clinical research 2017 Oct 26;23:5096-5105
TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.
Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF, Oben J, Pinzani M, Walczak H, Fusai G, Rosenberg WMC, Maini MK
Scientific reports 2017 Jul 17;7(1):5514
Scientific reports 2017 Jul 17;7(1):5514
The role of selected flavonols in tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) expression on activated RAW 264.7 macrophages.
Warat M, Sadowski T, Szliszka E, Król W, Czuba ZP
Molecules (Basel, Switzerland) 2015 Jan 8;20(1):900-12
Molecules (Basel, Switzerland) 2015 Jan 8;20(1):900-12
Chrysin, apigenin and acacetin inhibit tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) on activated RAW264.7 macrophages.
Warat M, Szliszka E, Korzonek-Szlacheta I, Król W, Czuba ZP
International journal of molecular sciences 2014 Jun 27;15(7):11510-22
International journal of molecular sciences 2014 Jun 27;15(7):11510-22
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ, Zhang L
Anticancer research 2014 Feb;34(2):729-34
Anticancer research 2014 Feb;34(2):729-34
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS
Stem cells translational medicine 2014 Feb;3(2):172-82
Stem cells translational medicine 2014 Feb;3(2):172-82
Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway.
Gupta SC, Francis SK, Nair MS, Mo YY, Aggarwal BB
The Journal of biological chemistry 2013 Nov 8;288(45):32343-56
The Journal of biological chemistry 2013 Nov 8;288(45):32343-56
Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis.
Hong S, Kim HY, Kim J, Ha HT, Kim YM, Bae E, Kim TH, Lee KC, Kim SJ
The Journal of biological chemistry 2013 Feb 1;288(5):3560-70
The Journal of biological chemistry 2013 Feb 1;288(5):3560-70
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, Espinoza-Delgado I, Ross DD
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Apr 1;19(7):1838-51
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Apr 1;19(7):1838-51
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
Kalb ML, Glaser A, Stary G, Koszik F, Stingl G
Journal of immunology (Baltimore, Md. : 1950) 2012 Feb 15;188(4):1583-91
Journal of immunology (Baltimore, Md. : 1950) 2012 Feb 15;188(4):1583-91
The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
Szliszka E, Helewski KJ, Mizgala E, Krol W
International journal of oncology 2011 Oct;39(4):771-9
International journal of oncology 2011 Oct;39(4):771-9
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang B, Cao L
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 May 15;17(10):3181-92
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 May 15;17(10):3181-92
Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A, Siegelin MD, Steinmüller A, von Deimling A, Lass U, Korn B, Mueller W
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Sep 1;15(17):5457-65
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Sep 1;15(17):5457-65
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
Stem cells (Dayton, Ohio) 2008 Nov;26(11):2955-63
Stem cells (Dayton, Ohio) 2008 Nov;26(11):2955-63
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Wu CH, Kao CH, Safa AR
Human gene therapy 2008 Jul;19(7):731-43
Human gene therapy 2008 Jul;19(7):731-43
Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS
Cancer research 2008 Dec 1;68(23):9614-23
Cancer research 2008 Dec 1;68(23):9614-23
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK
The Journal of experimental medicine 2007 Mar 19;204(3):667-80
The Journal of experimental medicine 2007 Mar 19;204(3):667-80
No comments: Submit comment
No validations: Submit validation data